Reducing the risk of death – a possible outcome in COPD patients

introduction: COPD is a leading cause of global mortality, particularly under-recognized and under-diagnosed. In 2020, it was the sixth leading cause of death in the US and has contributed to 4.72% of all-cause mortality (ACM) according to the global burden of disease study 2017. factors influencing COPD-related mortality include smoking, aging populations, comorbidities, sarcopenia, physical capacity, and lack of effective treatments. areas covered: this review discusses various factors influencing COPD-related mortality and analyzes observational studies and pivotal RCTs evaluating the impact of different therapies on ACM. expert opinion: COPD significantly impacts ACM, necessitating effective management strategies. smoking cessation is crucial in reducing mortality risk. aexacerbation management and comorbidity treatment are essential to improve patient outcomes. various therapeutic interventions, such as smoking cessation, vaccination, long-term oxygen therapy, and lung volume reduction surgery, have shown benefits in reducing mortality. pharmacotherapies might reduce the risk of mortality, although the current scientific evidences remain inconclusive. advances in pharmacological interventions, tailored treatment plans, and physical activity programs are vital. more robust and long-term studies, focusing on real-world data and addressing biases in treatment allocation, are needed to conclusively determine the efficacy of different therapies in reducing ACM in COPD patients.